Trials / Active Not Recruiting
Active Not RecruitingNCT06706310
Evaluate TQ-A3334 Combined Nucleoside (Acid) Analogs in the First Treatment/Treatment of Chronic HBV Infection
Evaluate TQ-A3334 Tablets Combined Nucleoside (Acid) Analogs in the Initial Treatment/Chronic Hepatitis B Virus (HBV) Infection Subjects of Chronic HBV Infection
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 116 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study uses random, double -blindness, placebo control, and phase multi -center test design. All subjects who meet the standards receive TQ-A3334 per tablet/placebo nucleoside (acid) analog. A total of 116 subjects are needed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | Placebo contains no active substance. |
| DRUG | TQA3334 Tablet | Inhibit viral replication. |
| DRUG | Nucleoside (acid) analogs (NAs) | Inhibit viral replication. |
Timeline
- Start date
- 2024-12-04
- Primary completion
- 2025-06-22
- Completion
- 2026-06-01
- First posted
- 2024-11-26
- Last updated
- 2025-11-26
Locations
15 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06706310. Inclusion in this directory is not an endorsement.